{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:56:23Z","timestamp":1792688183724,"version":"4.5.0"},"reference-count":68,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T00:00:00Z","timestamp":1755129600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Up to 22% of cancer patients treated with immune checkpoint inhibitors (ICIs) can experience immune-related adverse events (irAEs) that mimic rheumatic disease, such as relapsing polychondritis (RP), which is a rare autoimmune disease that mainly manifests as inflammation of airway cartilage.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We report a case of RP induced by humanized recombinant anti-PD-1 monoclonal antibody therapy (tislelizumab). 18F-Fluorodeoxyglucose positron emission tomography\/ computed tomography (18F-FDG PET\/CT) contributed to the diagnosis of RP, and methylprednisolone was used to effectively control its progression. We also reviewed 13 publications on drug-induced RP in the context of cancer and analyzed the pathogenesis, ancillary tests, treatment, and prognosis of the cases described therein. <\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Including our case, 14 drug-related RP cases with a tumor background were analyzed. Patients usually develop related symptoms 3\u20135 months after initiating medication. The primary tumor involvement sites included the hematological system (5\/14, 35.71%), upper digestive tract (4\/14, 28.57%), skin (2\/14, 14.29%), reproductive system (2\/14, 14.29%), bone (1\/14,7.14%), and lung (1\/ 14, 7.14%). <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>18F-FDG PET\/CT plays a crucial role in diagnosing RP caused by PD-1 monoclonal antibodies. Early detection and the prompt administration of corticosteroids are crucial in effectively controlling the progression of RP, helping to alleviate symptoms and prevent further complications.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1619229","type":"journal-article","created":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T05:35:49Z","timestamp":1755149749000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Relapsing polychondritis following PD-1 blockade diagnosed via 18F-FDG PET\/CT and improved by steroid administration: a case report and literature review"],"prefix":"10.3389","volume":"16","author":[{"given":"Ruo-Wen","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Bo","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Xu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Qi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Na","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Yu","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Yang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-0160-6","article-title":"Immune-related adverse events of checkpoint inhibitors","volume":"6","author":"Ramos-Casals","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2020.1833857","article-title":"Tislelizumab: an investigational anti-Pd-1 antibody for the treatment of advanced non-small cell lung cancer (Nsclc)","volume":"29","author":"Liu","year":"2020","journal-title":"Expert Opin Investig Drugs"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1097\/jto.0000000000000500","article-title":"Upregulation of Pd-L1 by Egfr activation mediates the immune escape in Egfr-driven Nsclc: implication for optional immune targeted therapy for Nsclc patients with Egfr mutation","volume":"10","author":"Chen","year":"2015","journal-title":"J Thorac Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-078876","article-title":"Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: rationale-305 randomised, double blind, phase 3 trial","volume":"385","author":"Qiu","year":"2024","journal-title":"BMJ"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/oarrr.S142892","article-title":"Refractory relapsing polychondritis: challenges and solutions","volume":"10","author":"Lekpa","year":"2018","journal-title":"Open Access Rheumatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex406","article-title":"Relapsing polychondritis: A clinical review for rheumatologists","volume":"57","author":"Kingdon","year":"2018","journal-title":"Rheumatol (Oxford)"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-021-01186-3","article-title":"Relapsing polychondritis after treatment with Pd-1 blockade","volume":"40","author":"Ogimoto","year":"2022","journal-title":"Invest New Drugs"},{"key":"B8","doi-asserted-by":"publisher","first-page":"E43","DOI":"10.1002\/hed.26456","article-title":"Nivolumab-related tracheobronchial chondritis: extremely rare manifestation of an immune-related adverse effect","volume":"42","author":"Kuba","year":"2020","journal-title":"Head Neck"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1159\/000245996","article-title":"Cutaneous manifestations of relapsing polychondritis in a patient receiving goserelin for carcinoma of the prostate","volume":"195","author":"Labarthe","year":"1997","journal-title":"Dermatology"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.31662\/jmaj.2023-0071","article-title":"Relapsing polychondritis following Pd-1 blockade by an immune checkpoint inhibitor","volume":"6","author":"Mutoh","year":"2023","journal-title":"Jma J"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.6798-20","article-title":"Tracheobronchial chondritis associated with immune checkpoint blockade","volume":"60","author":"Asoh","year":"2021","journal-title":"Intern Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"Np705","DOI":"10.1177\/01455613221081912","article-title":"Tracheobronchial chondritis as an immune-related adverse event occurring during the administration of nivolumab for recurrent hypopharyngeal squamous cell carcinoma","volume":"103","author":"Someya","year":"2024","journal-title":"Ear Nose Throat J"},{"key":"B13","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/art.42317","article-title":"Clinical images: nivolumab-induced tracheobronchial chondritis in a patient with hypopharyngeal cancer","volume":"75","author":"Hamada-Ode","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1001\/archderm.143.1.89","article-title":"Relapsing polychondritis and Malignant lymphoma: is polychondritis paraneoplastic","volume":"143","author":"Yanagi","year":"2007","journal-title":"Arch Dermatol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/nejm199712113372408","article-title":"Weekly clinicopathological exercises. Case 38-1997. Inflammation of the ears, anemia, and fever 21 years after treatment for Hodgkin\u2019s disease","volume":"337","year":"1997","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.025726","article-title":"Recurrent auricular chondritis and cartilage repair","volume":"64","author":"Rozin","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/pl00011192","article-title":"Remitting seronegative symmetrical synovitis with pitting oedema in a patient with myelodysplastic syndrome and relapsing polychondritis","volume":"20","author":"Manganelli","year":"2001","journal-title":"Clin Rheumatol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s12328-021-01534-z","article-title":"Relapsing polychondritis occurring after esophageal cancer surgery: A case report with a literature review","volume":"15","author":"Mase","year":"2022","journal-title":"Clin J Gastroenterol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1177\/10600280231180197","article-title":"Hydroxyurea-associated relapsing polychondritis in a patient with myeloproliferative neoplasm","volume":"58","author":"Yava\u015fo\u011flu","year":"2024","journal-title":"Ann Pharmacother"},{"key":"B20","article-title":"Analysis of 533 cases of adverse drug reactions inducedby antineoplastic drugs","volume":"12","author":"Tang","year":"2022","journal-title":"Anti-tumor Pharm"},{"key":"B21","doi-asserted-by":"publisher","first-page":"199","DOI":"10.19803\/j.1672-8629.20230358","article-title":"285 cases of adverse drug reaction related to new antineoplastic drugs","volume":"21","author":"Xu","year":"2024","journal-title":"Chin J Pharmacovigilance"},{"key":"B22","doi-asserted-by":"publisher","first-page":"324","DOI":"10.19803\/j.1672-8629.20230467","article-title":"Adverse drug reaction induced by antineoplastic drugs in a cancer hospital: an analysis of 613 cases","volume":"21","author":"Huang","year":"2024","journal-title":"Chin J Pharmacovigilance"},{"key":"B23","doi-asserted-by":"publisher","first-page":"73","DOI":"10.2147\/itt.S126227","article-title":"Clinical features, predictive correlates, and pathophysiology of immune-related adverse events in immune checkpoint inhibitor treatments in cancer: A short review","volume":"6","author":"Yoest","year":"2017","journal-title":"Immunotargets Ther"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.bulcan.2018.07.005","article-title":"Physiopathological mechanisms of immune-related adverse events induced by anti-Ctla-4, anti-Pd-1 and anti-Pd-L1 antibodies in cancer treatment","volume":"105","author":"Passat","year":"2018","journal-title":"Bull Cancer"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e68","DOI":"10.1136\/annrheumdis-2018-213470","article-title":"Checkpoint inhibitor-associated immune arthritis","volume":"78","author":"Arnaud","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/ajco.13346","article-title":"Rheumatic immune-related adverse events induced by immune checkpoint inhibitors","volume":"17","author":"Zhong","year":"2021","journal-title":"Asia Pac J Clin Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.05.005","article-title":"Tislelizumab plus chemotherapy as first-line treatment for locally advanced or metastatic nonsquamous Nsclc (Rationale 304): A randomized phase 3 trial","volume":"16","author":"Lu","year":"2021","journal-title":"J Thorac Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-018-2160-x","article-title":"The binding of an anti-Pd-1 antibody to Fc\u03b3r\u03b9 Has a profound impact on its biological functions","volume":"67","author":"Zhang","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.08.004","article-title":"Fc\u03b3rs modulate the anti-tumor activity of antibodies targeting the Pd-1\/Pd-L1 axis","volume":"28","author":"Dahan","year":"2015","journal-title":"Cancer Cell"},{"key":"B30","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1186\/s13023-021-01861-x","article-title":"Clinical patterns and the evolution of relapsing polychondritis based on organ involvement: A Chinese retrospective cohort study","volume":"16","author":"Zhang","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1433235","article-title":"Preliminary response to tislelizumab plus chemotherapy drugs in patient with periampullary carcinoma: A report of one case and a literature review","volume":"15","author":"Tang","year":"2024","journal-title":"Front Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1190491","article-title":"Severe thyrotoxicosis induced by tislelizumab: A case report and literature review","volume":"13","author":"Huo","year":"2023","journal-title":"Front Oncol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"452","DOI":"10.3892\/ol.2024.14586","article-title":"Misdiagnosis of severe and atypical oxaliplatin\u2212Related hypersensitivity reaction following chemotherapy combined with pd\u22121 inhibitor: A case report and literature review","volume":"28","author":"Sun","year":"2024","journal-title":"Oncol Lett"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1148425","article-title":"Case report: life-threatening pancytopenia with tislelizumab followed by cerebral infarction in a patient with lung adenocarcinoma","volume":"14","author":"Gu","year":"2023","journal-title":"Front Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2016.02.013","article-title":"Relapsing polychondritis: A clinical update","volume":"15","author":"Longo","year":"2016","journal-title":"Autoimmun Rev"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1002\/art.41270","article-title":"Defining clinical subgroups in relapsing polychondritis: A prospective observational cohort study","volume":"72","author":"Ferrada","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-024-01113-9","article-title":"Relapsing polychondritis: clinical updates and new differential diagnoses","volume":"20","author":"Mertz","year":"2024","journal-title":"Nat Rev Rheumatol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.20452\/pamw.805","article-title":"Relapsing polychondritis: case report and literature review","volume":"119","author":"Pol","year":"2009","journal-title":"Pol Arch Med Wewn"},{"key":"B39","doi-asserted-by":"publisher","first-page":"92","DOI":"10.22203\/ecm.v012a11","article-title":"The structure and function of cartilage proteoglycans","volume":"12","author":"Roughley","year":"2006","journal-title":"Eur Cell Mater"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(18)42671-3","article-title":"Cartilage matrix proteins. An acidic oligomeric protein (Comp) detected only in cartilage","volume":"267","author":"Hedbom","year":"1992","journal-title":"J Biol Chem"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1042\/bj1830539","article-title":"Matrix proteins bound to associatively prepared proteoglycans from bovine cartilage","volume":"183","author":"Paulsson","year":"1979","journal-title":"Biochem J"},{"key":"B42","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1097\/00005792-197605000-00001","article-title":"Relapsing polychondritis: prospective study of 23 patients and a review of the literature","volume":"55","author":"McAdam","year":"1976","journal-title":"Med (Baltimore)"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1288\/00005537-197906000-00009","article-title":"Relapsing polychondritis\u2013report of ten cases","volume":"89","author":"Damiani","year":"1979","journal-title":"Laryngoscope"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-104-1-74","article-title":"Relapsing polychondritis. Survival and predictive role of early disease manifestations","volume":"104","author":"Michet","year":"1986","journal-title":"Ann Intern Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1097\/rlu.0000000000001890","article-title":"Incidental case of relapsing polychondritis detected by 18f-Fdg Pet\/Ct","volume":"43","author":"Kaida","year":"2018","journal-title":"Clin Nucl Med"},{"key":"B46","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1097\/rlu.0000000000004698","article-title":"Relapsing polychondritis: the oto-rhino-tracheobronchial triad on 18 F-Fdg Pet\/Ct","volume":"48","author":"Kwok","year":"2023","journal-title":"Clin Nucl Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1097\/rlu.0000000000003060","article-title":"18f-Fdg Pet\/Ct imaging of vasculitis complicated with relapsing polychondritis","volume":"45","author":"Kamada","year":"2020","journal-title":"Clin Nucl Med"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-021-05650-3","article-title":"Quantitative imaging biomarkers of immune-related adverse events in immune-checkpoint blockade-treated metastatic melanoma patients: A pilot study","volume":"49","author":"Hribernik","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B49","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1093\/rheumatology\/kez243","article-title":"Fluorodeoxyglucose positron emission tomography\/computed tomography in the diagnosis, assessment of disease activity and therapeutic response in relapsing polychondritis","volume":"59","author":"Sharma","year":"2020","journal-title":"Rheumatol (Oxford)"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1259\/bjr.20150695","article-title":"(18)F-Fdg Pet-Ct: A powerful tool for the diagnosis and treatment of relapsing polychondritis","volume":"89","author":"Lei","year":"2016","journal-title":"Br J Radiol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1007\/s00393-014-1560-3","article-title":"Relapsing polychondritis. Primary and follow-up diagnostics with (18)F-Fdg-Pet\/Ct","volume":"74","author":"Sch\u00fcle","year":"2015","journal-title":"Z Rheumatol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3978\/j.issn.2072-1439.2014.08.21","article-title":"Fdg Pet-Ct combined with Tbna for the diagnosis of atypical relapsing polychondritis: report of 2 cases and a literature review","volume":"6","author":"Lei","year":"2014","journal-title":"J Thorac Dis"},{"key":"B53","doi-asserted-by":"publisher","first-page":"e7503","DOI":"10.1097\/md.0000000000007503","article-title":"18f-Fdg Pet\/Ct is an ideal imaging modality for the early diagnosis of relapsing polychondritis: A case report","volume":"96","author":"Wang","year":"2017","journal-title":"Med (Baltimore)"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/s0161-6420(86)33695-9","article-title":"Ocular and systemic findings in relapsing polychondritis","volume":"93","author":"Isaak","year":"1986","journal-title":"Ophthalmology"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu147","article-title":"Utility of fluorodeoxyglucose positron emission tomography\/computed tomography for early diagnosis and evaluation of disease activity of relapsing polychondritis: A case series and literature review","volume":"53","author":"Yamashita","year":"2014","journal-title":"Rheumatol (Oxford)"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12051163","article-title":"(18)F-Fdg pet parameters and radiomics features analysis in advanced Nsclc treated with immunotherapy as predictors of therapy response and survival","volume":"12","author":"Polverari","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2021.03.001","article-title":"The value of (18)F-Fdg Pet\/Ct in predicting the response to Pd-1 blocking immunotherapy in advanced nsclc patients with high-level Pd-L1 expression","volume":"22","author":"Vekens","year":"2021","journal-title":"Clin Lung Cancer"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1007\/s12149-020-01539-7","article-title":"Fdg-pet biomarkers associated with long-term benefit from first-line immunotherapy in patients with advanced non-small cell lung cancer","volume":"34","author":"Seban","year":"2020","journal-title":"Ann Nucl Med"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1274677","article-title":"Development and validation of diagnostic and activity-assessing models for relapsing polychondritis based on laboratory parameters","volume":"14","author":"Liu","year":"2023","journal-title":"Front Immunol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1002\/art.40043","article-title":"Review: immune-related adverse events with use of checkpoint inhibitors for immunotherapy of cancer","volume":"69","author":"Suarez-Almazor","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1056\/nejm197811302992202","article-title":"Antibodies to type ii collagen in relapsing polychondritis","volume":"299","author":"Foidart","year":"1978","journal-title":"N Engl J Med"},{"key":"B62","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1093\/cei\/uxad014","article-title":"Progress and challenges in the use of blood biomarkers in relapsing polychondritis","volume":"212","author":"Liu","year":"2023","journal-title":"Clin Exp Immunol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-60-4-653","article-title":"Relapsing polychondritis. Clinical and pathologic features in fourteen cases","volume":"60","author":"Kaye","year":"1964","journal-title":"Ann Intern Med"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.revmed.2023.05.005","article-title":"French practical guidelines for the diagnosis and management of relapsing polychondritis","volume":"44","author":"Arnaud","year":"2023","journal-title":"Rev Med Interne"},{"key":"B65","first-page":"384","article-title":"Progress in the diagnosis and treatment of relapsing polychondritis","author":"Shen","year":"2005","journal-title":"Int J Respiration"},{"key":"B66","doi-asserted-by":"publisher","first-page":"e21463","DOI":"10.7759\/cureus.21463","article-title":"Early recognition and treatment of relapsing polychondritis","volume":"14","author":"Yanagihara","year":"2022","journal-title":"Cureus"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2022.2048647","article-title":"Biologic therapy in relapsing polychondritis: navigating between options","volume":"22","author":"Padoan","year":"2022","journal-title":"Expert Opin Biol Ther"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2019.0013","article-title":"Management of immunotherapy-related toxicities, version 1.2019","volume":"17","author":"Thompson","year":"2019","journal-title":"J Natl Compr Canc Netw"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1619229\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T05:35:52Z","timestamp":1755149752000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1619229\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,14]]},"references-count":68,"alternative-id":["10.3389\/fimmu.2025.1619229"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1619229","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,14]]},"article-number":"1619229"}}